Skip to main content
. 2020 May 13;69(10):2021–2031. doi: 10.1007/s00262-020-02596-7

Fig. 2.

Fig. 2

CpG-C hinders the development of CT26 surface-hepatic metastases and reduces liver weight. CpG-C (100 µg/mouse) or PBS (control) were injected twice, 24 h prior and 24 h following 20,000 CT26 tumor cell inoculation. CpG-C treatment significantly reduced number of metastases (a), and liver weight (b). The average weight of livers without metastases is approximately 1 g. Data are expressed as mean + SEM. * indicates a significant difference from PBS control levels